Annual secretarial compliance report for the year 2024-25.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma has filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under SEBI's Listing Regulations. The report, issued by Practicing Company Secretary Jinesh Dedhia & Associates, reviewed the company's compliance with SEBI regulations, the Companies Act, and secretarial standards. Across all 13 areas examined — including secretarial standards, board policies, website disclosures, director eligibility, subsidiary compliance, document preservation, board performance evaluation, related party transactions, insider trading rules, and timely event disclosures — the company was found to be compliant. No actions were taken by SEBI or stock exchanges against the company, its promoters, directors, or subsidiaries during the year. There was also no resignation of statutory auditors and no additional non-compliances were observed.
This is a routine, mandatory annual filing with a clean compliance record, indicating sound corporate governance. No material impact on the stock price is expected, though it reassures investors about the company's regulatory standing.